Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

Key Inclusion Criteria: * Must be of at least 50 years of age, at the time of signing the informed consent. * Have a clinical diagnosis of stable, clinically typical actinic keratosis. * Have at least 3 actinic keratosis lesions contained within contiguous treatment regions of face and/or scalp and/or back of hands. * Must agree not to use any product on the treatment area during the entire course of study except for Investigator-approved cleanser, sunscreen, wash, and non-medicated makeup. * Must be willing to comply with sun avoidance measures for all exposed areas including use of Investigator-approved sunscreen and/or hats, have limited sun exposure time, and have no tanning bed use. * Must be in good general health (ECOG 0-1) * Participants of reproductive potential must agree to use double effective contraception from screening until 90 days after discontinuing study treatment. * Female participants who had a menstrual cycle within 2 years prior to screening must have a negative serum pregnancy test at screening and a negative urine pregnancy test on their first treatment day. * Must be capable of giving signed informed consent Key Exclusion Criteria: * Known or suspected hypersensitivity to any of the excipients of bimiralisib gel. * Clinically atypical and/or rapidly changing actinic keratosis lesions in the treatment area. * Clinical evidence of severe, uncontrolled autoimmune, cardiovascular, gastrointestinal, hematological, hepatic, neurologic, pulmonary or rena…